Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Abstract
Accumulating evidence has shown that PD-L1 expression is associated with clinicopathological features in various human malignancies. We searched for correlations between PD-L1 expression and clinicopathological data in esophageal squamous cell carcinoma (ESCC) patients. PD-L1 expression in primary tumors from 278 patients was evaluated using immunohistochemistry (IHC) in ESCC tissue microarray. Survival curves were constructed by using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard regression models were performed to identify associations with outcome variables. Overall, tumoral PD-L1 expression (≥10%, 20% or 30% as cut-off value) was associated with favorable DFS and OS upon multivariate analysis. When the patients stratified into stage I-II (168, 60.4%) and stage III-IV (110, 39.6%), or with lymph node metastasis (133, 47.8%), the prognostic role was not consistent. In patients with stage I-II disease, tumoral PD-L1 expression (≥5%, 10%, 20% or 30%) was associated with better DFS and OS upon multivariate analysis. In patients without lymph node metastasis, tumoral PD-L1 expression (≥1%, 5%, 10%, 20%, or 30%) was associated with improved DFS and OS in univariate or multivariate analysis. However, PD-L1 expression was not correlated with prognosis in patients with stage III-IV disease or with lymph node metastasis. Our results for the first time showed the prognostic role of tumoral PD-L1 expression was variable in different stages and lymph node status of ESCC. Tumoral PD-L1 expression was independent favorable predictor in ESCC patients with Stage I-II disease or without lymph node metastasis, not in stage III-IV or lymph node metastasis.
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of thoracic surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of thoracic surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China. Department of Pathology, School of Basic Medical Sciences & Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China. MeSH
AdultAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellChi-Square DistributionDisease ProgressionDisease-Free SurvivalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProportional Hazards ModelsRetrospective StudiesRisk FactorsTime FactorsTissue Array AnalysisTreatment Outcome
Pub Type(s)
Journal Article